Matinas BioPharma Holdings, Inc. (MTNB): Shareholders' Equity
$4.83M
As of 2025-12-31
$1.80M
As of 2026-06-30
-49.1%
3-year compound annual growth
-40.3%
5-year compound annual growth
-2.3%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.83M | -36.4% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $7.59M | -60.6% | 2026-03-31, Balance as of period end |
| 2023-12-31 | $19.25M | -47.5% | 2025-04-15, Balance as of period end |
| 2022-12-31 | $36.64M | -30.2% | 2024-03-27, Balance as of period end |
| 2021-12-31 | $52.49M | -17.6% | 2023-03-15, Balance as of period end |
| 2020-12-31 | $63.73M | +92.8% | 2022-03-11, Balance as of period end |
| 2019-12-31 | $33.05M | +104.8% | 2021-03-29, Balance as of period end |
| 2018-12-31 | $16.14M | +51.1% | 2020-03-09, Balance as of period end |
| 2017-12-31 | $10.68M | +49.4% | 2019-04-01, Balance as of period end |
| 2016-12-31 | $7.15M | +17.7% | 2018-03-16, Balance as of period end |
| 2015-12-31 | $6.07M | +172.6% | 2018-03-16, Balance as of period end |
| 2014-12-31 | $2.23M | -78.7% | 2017-03-31, Balance as of period end |
| 2013-12-31 | $10.47M | n/a | 2015-03-31, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Matinas BioPharma Holdings, Inc. (MTNB) | 2025-12-31 | $4.83M | -36.4% |
| Telomir Pharmaceuticals, Inc. (TELO) | 2025-12-31 | $5.91M | +819.6% |
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | -$30.15M | n/m |
| Ensysce Biosciences, Inc. (ENSC) | 2025-12-31 | $3.21M | -13.3% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $1.47M | -18.2% |
| Serina Therapeutics, Inc. (SER) | 2025-12-31 | -$37.0K | n/m |
| Oncolytics Biotech Inc (ONCY) | 2025-12-31 | -$3.80M | n/m |
| OS Therapies Inc (OSTX) | 2025-12-31 | -$6.10M | n/m |
| Rocket One Inc. (RKTO) | 2025-12-31 | $6.15M | -10.6% |
Compare MTNB, TELO, CPMD, ENSC side by side · Screen every company in Pharmaceutical Preparations ↗